FDA begins new comment period for hemostatic-device rule

09/15/2008 | FDAnews

The FDA has reopened the time period for comments on the proposed rule and guidance for absorbable hemostatic devices, saying it will accept submissions until Oct. 14. The move is in response to a petition that urged the FDA to delay issuing the rule and guidelines until the public release of a revised administrative record.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC